PCV Vaccine Economic Inequalities

This is a news story, published by MSN, that relates primarily to Vaccine news.

Vaccine news

For more Vaccine news, you can click here:

more Vaccine news

News about vaccine development

For more vaccine development news, you can click here:

more vaccine development news

MSN news

For more news from MSN, you can click here:

more news from MSN

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about

affordable vaccines

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest vaccine costs news, lower vaccine prices news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

pneumococcal conjugate vaccine

Medical Xpress - medical research advances and health news

•

Richer countries are getting unfair access to life-saving vaccines, research shows

Summary

Nutrition label

89% Informative

Pneumococcal conjugate vaccine, known as PCV , prevents around 30 percent of pneumonia, the most common cause of childhood deaths worldwide.

But new research has uncovered inequalities in how net economic benefits of the vaccine are distributed around the world.

This is despite the fact that most of the world's disease burden is concentrated in low and middle-income countries.

Vaccine prices could be set based on the expected economic benefits they provide at a country level.

Cross subsidization can be strengthened by charging higher prices to wealthy countries to encourage them to "pay their share" In 2024 , vaccine inequality remains a significant barrier to global health and this is likely to get worse as more products reach licensure.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful